992 related articles for article (PubMed ID: 34530847)
1. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
2. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
4. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
Anderson M; Levy M
J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
[TBL] [Abstract][Full Text] [Related]
5. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
6. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
Crout TM; Parks LP; Majithia V
Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of neuromyelitis optica].
Fujihara K
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):129-35. PubMed ID: 22576570
[TBL] [Abstract][Full Text] [Related]
9. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
11. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
Pittock SJ; Zekeridou A; Weinshenker BG
Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
13. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
14. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
Tradtrantip L; Asavapanumas N; Verkman AS
Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
[No Abstract] [Full Text] [Related]
16. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
Jarius S; Wildemann B
Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
[TBL] [Abstract][Full Text] [Related]
17. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
18. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
[TBL] [Abstract][Full Text] [Related]
19. [Neuromyelitis Optica Spectrum Disorder].
Misu T
Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]